Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin

Xanthine oxidase inhibitors febuxostat and allopurinol are commonly used in the treatment of gout. Febuxostat inhibits the breast cancer resistance protein (BCRP) in vitro. Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. In this study,...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Transl Sci
Hoofdauteurs: Lehtisalo, Minna, Keskitalo, Jenni E., Tornio, Aleksi, Lapatto‐Reiniluoto, Outi, Deng, Feng, Jaatinen, Taina, Viinamäki, Jenni, Neuvonen, Mikko, Backman, Janne T., Niemi, Mikko
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2020
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7719384/
https://ncbi.nlm.nih.gov/pubmed/32453913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12809
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items